Navigation Links
VG Life Sciences, Inc. Announces the Initiation of IND-Enabling Animal Safety Studies
Date:11/4/2013

SANTA BARBARA, Calif., Nov. 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. is a publicly traded (VGLS) biotechnology company focused on developing treatments for patients suffering autoimmune and infectious diseases.

(Logo: http://photos.prnewswire.com/prnh/20131031/LA07859LOGO)

VG Life Sciences, Inc. has contracted ITR Laboratories Canada, Inc. to perform FDA IND enabling animal safety studies with its patented peptide VG1177. The studies will address the optimum route of administration and will provide key toxicological, pharmacological, genotoxicological, and toxicokinetic data for IND applications that VG Life Sciences, Inc. will submit for FDA review.

The inventor of VG1177 is Dr. Karen Newell Rogers, PhD at Texas A&M University School of Medicine and Chief Scientist at VG Life Sciences. "These animal safety studies mark an important step in advancing VG1177 from technology to treatment, and will provide key safety data in support of our coming clinical trials," said Dr. Newell Rogers.

Results from the studies are expected to conclude by July 2014.

"At our restructuring in July we identified three important initiatives that we needed to complete this year: raise additional capital, begin audited financials and start animal safety studies. We are proud we completed all these goals in less than 4 months. This sets the stage for key milestones in 2014," said John Tynan, VG Life Sciences' President and CEO. "Thus we are pleased to announce the start of this important pre-clinical study bringing us closer to monetize our intellectual property as outlined in our July 2013 Letter to Shareholders."

The VG1177 peptide prevents the survival of pro-inflammatory cells under conditions where inflammation is unwanted, thereby allowing the body's natural containment systems to provide protection from harm.

About ITR Laboratories Canada, Inc.

Montreal-based ITR Laboratories Canada Inc. is a privately held contract research organization specializing in non-clinical studies for pharmaceutical and biotechnology companies. For more information visit www.itrlab.com.

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company working on discovering and developing drug therapies for infectious diseases, cancer and many autoimmune diseases. VGLS controls over 50 US and international patents and patents pending protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.

Contact:

Alexandria Sumner, Director of Corporate Communications
VG Life Sciences, Inc.
Phone:  (805) 679-6763
Email:  asumner@vglifesciences.com


'/>"/>
SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
3. KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
4. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
5. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
8. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
9. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
10. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
11. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media ... Janet Yellen and company to wait until March 2017 for an interest rate increase, ... Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):